Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan | Synapse
March 7, 2026Open Access
Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan
Key Points
This analysis aims to evaluate the cost-effectiveness of immune checkpoint inhibitors compared to platinum-based chemotherapy for treating advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression in Japan.
Cost-effectiveness analysis comparing pembrolizumab, nivolumab plus ipilimumab, and atezolizumab against platinum-based chemotherapy
Assessment of patient outcomes and treatment costs
Analysis focused on patients with PD-L1 TPS ≥ 50%
Pembrolizumab is identified as a cost-effective treatment option for advanced NSCLC with high PD-L1 expression
Nivolumab combined with ipilimumab is also considered viable
Atezolizumab is ranked as the least cost-effective option among the treatments assessed
Abstract
Pembrolizumab is a cost-effective first-line treatment for advanced NSCLC with PD-L1 TPS ≥ 50% in Japan. Nivolumab plus ipilimumab is also a viable option. Atezolizumab is the least cost-effective.